Table 3.
AEs in greater than or equal to 10% of duvelisib-treated patients
| AE | All grades | Grade 3 and above | ||
|---|---|---|---|---|
| Duvelisib, n (%) | Ofatumumab, n (%) | Duvelisib, n (%) | Ofatumumab, n (%) | |
| Any AE | 156 (99) | 144 (93) | 138 (87) | 75 (48) |
| Hematologic AEs | ||||
| Neutropenia | 52 (33) | 32 (21) | 48 (30) | 27 (17) |
| Anemia | 36 (23) | 16 (10) | 20 (13) | 8 (5) |
| Thrombocytopenia | 23 (15) | 9 (6) | 12 (8) | 3 (2) |
| Nonhematologic AEs | ||||
| Diarrhea | 80 (51) | 19 (12) | 23 (15) | 2 (1) |
| Pyrexia | 45 (29) | 16 (10) | 4 (3) | 1 (1) |
| Nausea | 37 (23) | 17 (11) | 0 | 0 |
| Cough | 33 (21) | 22 (14) | 2 (1) | 0 |
| Pneumonia | 29 (18) | 9 (6) | 22 (14) | 2 (1) |
| Constipation | 26 (17) | 13 (8) | 1 (1) | 0 |
| URTI | 25 (16) | 12 (8) | 0 | 0 |
| Vomiting | 23 (15) | 10 (7) | 0 | 0 |
| Bronchitis | 21 (13) | 13 (8) | 5 (3) | 1 (1) |
| Colitis | 21 (13) | 2 (1) | 19 (12) | 1 (1) |
| Fatigue | 20 (13) | 19 (12) | 2 (1) | 2 (1) |
| Decreased appetite | 20 (13) | 5 (3) | 0 | 1 (1) |
| Weight decreased | 18 (11) | 3 (2) | 0 | 0 |
| Asthenia | 18 (11) | 17 (11) | 3 (2) | 4 (3) |
| Abdominal pain | 16 (10) | 3 (2) | 3 (2) | 0 |
| Dyspnea | 16 (10) | 9 (6) | 4 (3) | 0 |
| Rash | 16 (10) | 18 (12) | 3 (2) | 1 (1) |
URTI , upper respiratory tract infection.